The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Therapeutic optimization for molecular subtypes of NCSLC with multiomics
Lukas Delasos, DO, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, shares his insights on optimizing therapeutic approaches for aggressive molecular subtypes of metastatic non-small cell lung cancer (NCSLC). He advises that the most effective approach is a multiomic one, taking into consideration different levels of biological data to develop the best therapeutic strategy for patients. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
